Decker Retirement Planning
VRTX icon

Decker Retirement Planning’s Vertex Pharmaceuticals VRTX Stock Holding History

Decker Retirement Planning’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-6
Closed -$2.98K – 484
2026
Q2 		$2.98K Buy
+6
New +$2.66K ﹤0.01% 326

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Decker Retirement Planning's VRTX Position: Q3 2026 in Review

Decker Retirement Planning sold out of Vertex Pharmaceuticals (VRTX) in Q3 2026, closing a stake of 6 shares — an estimated $2.98K sold.

Decker Retirement Planning first reported a position in VRTX in Q2 2026 and held it in 1 quarter. The position peaked at $2.98K in Q2 2026. 1,383 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Decker Retirement Planning reported no remaining Vertex Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Decker Retirement Planning sold 6 Vertex Pharmaceuticals shares in Q3 2026, an estimated $2.98K.
  • Decker Retirement Planning first reported a position in Vertex Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • Decker Retirement Planning's Vertex Pharmaceuticals position peaked at $2.98K in Q2 2026.
  • 1,383 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Decker Retirement Planning's 13F filing for Q3 2026, filed 19 Oct 2026.